Study: MeMed's blood test distinguishes between bacterial, viral infections in children 

The ImmunoXpert test is CE-marked, but is not yet approved in the U.S. (MeMed)

Israeli diagnostics player MeMed reported data from a study of more than 500 children and adolescents showing that its blood test can accurately tell the difference between a bacterial and a viral infection. 

MeMed's CE-marked ImmunoXpert test measures immune system biomarkers in a blood sample and uses algorithms that recognize patterns to distinguish between viral and bacterial infections. The company aims to cut down on the misuse of antibiotics, which can lead to ineffective treatment of infections and the emergence of antibiotic-resistant strains of bacteria. 

The Pathfinder study is an international, external, double-blinded study that involved 597 patients aged three months to 18 years with a suspected acute infection, as well as control patients without infection. The patients included those with respiratory tract infections, urinary tract infections and those with a fever that had no identifiable source, the company said. 


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

The results show that the ImmunoXpert test accurately distinguished between viral and bacterial infections with 94% sensitivity and 90% specificity. The test also bested routine laboratory parameters, such as white blood cell count, which are used to manage patients with infections. The findings are published in the journal Pediatrics. 

RELATED: Karius reels in $50M to ramp up infectious disease liquid biopsy 

"[We] found that the test may be applicable to harder-to-diagnose cases, as it assigned a clear diagnosis to the majority of cases where there was no agreement on the underlying cause of infection among three independent senior physicians examining the patient medical records. This is a critical capability as it allows clinicians to use the test confidently even when they are unsure what is causing the infection," said Isaac Srugo, M.D., chief of the pediatric department and director of the microbiology laboratory at Bnai-Zion Medical Center in Israel, who co-led the study. 

MeMed is also developing ImmunoPOC, a benchtop system that quickly and accurately differentiates between bacterial and viral infections at the point of care. 

Suggested Articles

Boston Scientific’s deep brain stimulation implant for treating Parkinson’s disease has been approved by the FDA as safe to use within an MRI.

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.